Biodesix, Inc. (BDSX)
| Market Cap | 295.01M +388.7% |
| Revenue (ttm) | 102.94M +34.5% |
| Net Income | -27.76M |
| EPS | -3.13 |
| Shares Out | 10.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,163 |
| Open | 29.30 |
| Previous Close | 29.06 |
| Day's Range | 27.52 - 29.99 |
| 52-Week Range | 5.26 - 31.97 |
| Beta | 0.55 |
| Analysts | Strong Buy |
| Price Target | 37.33 (+33.51%) |
| Est. Earnings | Nov 2, 2026 |
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to... [Read more]
Financial Performance
In 2025, Biodesix's revenue was $88.50 million, an increase of 24.08% compared to the previous year's $71.32 million. Losses were -$35.27 million, -17.86% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for BDSX stock is "Strong Buy." The 12-month stock price target is $37.33, which is an increase of 33.51% from the latest price.
News
Biodesix price target raised to $38 from $27 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Biodesix (BDSX) to $38 from $27 and keeps a Buy rating on the shares. The company’s new tumor-informed and tumor-naive Molecular Residual…
Biodesix advances two programs for Molecular Residual Disease monitoring
Biodesix (BDSX) announced strategic progress in two collaborative programs for tumor-informed and tumor-naive Molecular Residual Disease – or MRD – solutions intended to support cancer centers and cli...
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
Biodesix-led tumor-informed and tumor-naïve programs draw on the company's bioinformatics and diagnostics test development expertise Biodesix-led tumor-informed and tumor-naïve programs draw on the co...
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Industry-leading QA/RA excellence accelerates patient access to Biodesix Lab testing, which helps improve overall outcomes for patients with lung nodules Industry-leading QA/RA excellence accelerates ...
Biodesix to Participate in Upcoming Investor Conferences
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present ...
Biodesix Transcript: Canaccord Genuity's 46th Annual Growth Conference
Strong sales force expansion and clinical evidence are driving robust revenue growth and high gross margins. The company is focused on profitability, pipeline development, and leveraging its infrastructure for future opportunities, with major updates expected at the AMP meeting.
Biodesix price target raised to $35 from $27 at Canaccord
Canaccord raised the firm’s price target on Biodesix (BDSX) to $35 from $27 and keeps a Buy rating on the shares. The firm said they the company reported 2Q26 results…
Biodesix price target raised to $27 from $26 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Biodesix (BDSX) to $27 from $26 and keeps a Buy rating on the shares. The firm cites the company’s…
Biodesix Earnings Call Transcript: Q2 2026
Q2 2026 saw 34% revenue growth and expanding gross margins, driven by strong diagnostic test adoption in both primary care and pulmonology. Operational discipline improved profitability metrics, and the company reaffirmed its full-year revenue outlook of $108–$114 million.
Biodesix Earnings release: Q2 2026
Biodesix released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Biodesix Quarterly report: Q2 2026
Biodesix has published its Q2 2026 quarterly earnings report on August 5, 2026.
Biodesix Announces Second Quarter 2026 Results and Highlights
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Co...
Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present i...
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarte...
Biodesix management to meet virtually with Craig Hallum
Virtual Meeting to be held on July 9 hosted by Craig Hallum.
Roth starts Biodesix at Buy, says positioned to deliver durable growth
Roth Capital analyst Max Masucci initiated coverage of Biodesix (BDSX) with a Buy rating and $32 price target The firm believes Biodesix is positioned to deliver durable top-line growth and…
Biodesix initiated with a Buy at Roth Capital
Roth Capital analyst Max Masucci initiated coverage of Biodesix (BDSX) with a Buy rating and $32 price target
Biodesix price target raised to $27 from $22 at Canaccord
Canaccord raised the firm’s price target on Biodesix (BDSX) to $27 from $22 and keeps a Buy rating on the shares. The firm updated its model following investor/management meetings. Investors…
Biodesix initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Biodesix (BDSX) with a Buy rating and $26 price target Biodesix is a commercial-stage diagnostics company concentrated on lung disease, combining genomics, proteo...
Biodesix Transcript: 46th Annual William Blair Growth Stock Conference
Strong revenue and margin growth driven by expanding adoption of proprietary lung nodule tests, with a focus on execution, operational efficiency, and targeted outreach to pulmonologists and primary care. Ongoing clinical studies and new technologies are expected to further expand the market opportunity.
Biodesix files to sell 375,000 shares of common stock for holders
16:40 EDT Biodesix (BDSX) files to sell 375,000 shares of common stock for holders
Biodesix Registration statement: Registration filing
Biodesix filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professional...
Biodesix price target raised to $22 from $20 at Canaccord
Canaccord raised the firm’s price target on Biodesix (BDSX) to $22 from $20 and keeps a Buy rating on the shares. The firm said the price target increase is primarily…
Biodesix reports Q1 EPS (81c) vs. ($1.52) last year
Reports Q1 revenue $22.29M, consensus $23.18M. “Biodesix (BDSX) delivered exceptional first quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services...